Riskpilot← Back to searchSign inGet full accessOy Chroma-Lab Ab
OYActiveY-tunnus 0130959-5Kraputie 8-AWholesale of pharmaceutical and medical goods · NACE 4646Est. 19761 employees
Revenue 2025
EUR 98K
-51% vs 2024
EBITDA margin
-26.0%
-180% vs 2024
Equity ratio
95.2%
Financial strength
Net profit 2025
EUR -26K
-185% vs 2024
| Revenue | EUR 98K | -51% |
| EBITDA | EUR -25K | -180% |
| Net profit | EUR -26K | -185% |
| Total assets | EUR 131K | -99% |
| Equity | EUR 125K | -99% |
| Employees | 1 | — |
Legal name
Oy Chroma-Lab Ab
Y-tunnus number
0130959-5
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
23. huhtikuuta 1976
Share capital
EUR 8 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on laboratorio-ja sairaala-alan laitteiden, tarvikkeiden ja koneiden vähittäis- ja tukkumyynti sekä siihen liittyvä toiminta. Yhtiö voi myydä, omistaa ja hallita kiinteää omaisuutta ja osakkeita.
Address
Kraputie 8-A
Phone
+3580103963333
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 169 | 181 | 18 044 | 201 | 98 |
| Staff expenses | −74 | −66 | −6 062 | −46 | −41 |
| EBITDA | 4 | −14 | −9 | 32 | −25 |
| Depreciation & amort. | −1 | −1 | −78 | −1 | −1 |
| EBIT | 3 | −14 | −10 | 31 | −26 |
| Net financials | 1 | −0 | −0 | −0 | −0 |
| Profit before tax | 4 | −15 | −10 | 31 | −26 |
| Tax | −4 | −0 | −0 | −0 | −0 |
| Net profit | 9 | −15 | −10 | 31 | −26 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 161 | 142 | 147 | 17 380 | 131 |
| Equity | 145 | 130 | 120 | 15 075 | 125 |
| Long-term debt | — | — | 0 | 0 | 0 |
| Short-term debt | 16 | 12 | 27 | 2 305 | 6 |
| Total debt | 16 | 12 | 27 | 2 305 | 6 |
EBITDA margin
-26.0%
This company
15.8%
Market median
-265% vs market
20212025
Equity ratio
95.2%
This company
38.2%
Market median
+149% vs market
20212025
Return on equity
-21.0%
This company
18.4%
Market median
-214% vs market
20212025
Net profit margin
-26.7%
This company
8.1%
Market median
-430% vs market
20212025
Asset turnover
0.75×
This company
1.12×
Market median
-33% vs market
20212025
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via PRH / YTJ · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via PRH / YTJ · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via PRH / YTJ · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via PRH / YTJ · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PM Deputy auditor | Deputy auditor | 2008 |
FO Deputy Member | Deputy Member | 2020 |
| Former (1) | ||
TH Audit | Audit | 2008 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairperson | 2020 | |
| Board of Directors | 2020 | |
| Former (1) | ||
| Chairperson | 2017 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Oy Chroma-Lab Ab also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Teija Helena Moisala | Audit | 0 companies |
| Päivi Maarit Sten | Deputy auditor | 0 companies |
| Frank Oliver Söderholm | Deputy Member | 0 companies |
| Huki Kai Christian Söderholm | Chairperson | 0 companies |
| Cecilia Solveig Silfver | Board of Directors | 0 companies |
| Siw Ingeborg Söderholm | Chairperson | 0 companies |